Kalkine has a fully transformed New Avatar.

small-cap

Should You Keep a Watch on This Healthcare Stock - SELB

Mar 17, 2022 | Team Kalkine
Should You Keep a Watch on This Healthcare Stock - SELB

 

Selecta Biosciences Inc.

Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical-stage biopharmaceutical company, which uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses.

Key Updates:

  • Decline in cash balance: In FY21, the company reported a reduction in cash and cash equivalents at USD 114.0 million, as compared to USD 138.6 million in FY20. This remains a key concern and might hinder the company’s liquidity.
  • Highly leveraged balance sheet: The company’s D/E ratio stands higher at 1.14x in FY21, as compared to the industry median of zero. This might hinder the company’s overall financial flexibility. Additionally, the investors of SELB are prone to higher balance sheet risk as the company reported its long-term debt to total capital of 40.9% in FY21, as compared to the industry median of 0.1%.
  • Collaboration with Ginkgo Bioworks: Recently, the company collaborated with Ginkgo Bioworks, a leading horizontal platform for cell programming and would develop tolerogenic therapies that selectively mitigate unwanted immune responses. The group is focused to develop safer and more effective next-generation gene therapy viral capsids. 

Stock recommendation:

Despite a higher income in FY21, the company ended with net loss due to rise in input costs. Continuation of the above trend remains a key concern for the group as it might lead to higher accumulated deficit for the firm. The stock derailed ~53% and ~63% in the last three months and six months, respectively, which indicates higher selling pressure. Moreover, the stock closed below its 50-days and 100-days simple moving averages, indicating a bearish pattern. The stock is available at a higher valuation of price to book value of 8.1x on TTM basis, as compared to the industry (Healthcare) median of 1.8x. Hence, considering the aforesaid facts, we give a ‘Watch’ stance on the stock of SELB at the closing price of USD 1.50 on March 16, 2022.

1-Year Technical Price Chart (as on March 16, 2022). Source: REFINITIV, Analysis by Kalkine Group.

Technical Analysis Summary

Note: Investors can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario.


Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.